Nebivolol Hydrochloride Aurobindo (Nebivolol)

Nebivolol is a beta‑adrenergic blocker used primarily in the management of hypertension and related cardiovascular conditions.

• Hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension.
• Heart failure: improves cardiac output and may reduce hospitalization in patients with chronic heart failure with reduced ejection fraction.
• Left ventricular hypertrophy: helps regress cardiac remodeling associated with high blood pressure.

• Nebivolol selectively antagonizes β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and contractility, which lowers cardiac output. In addition, it stimulates endothelial nitric oxide synthase, enhancing nitric oxide release and causing vasodilation of peripheral vessels. The combined β1‑blockade and nitric‑oxide‑mediated vasodilation result in a net reduction of systemic blood pressure. These actions also improve arterial compliance and reduce peripheral resistance, contributing further to antihypertensive effect.

Nebivolol may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Headache: mild to moderate headache.
• Dizziness: sensation of light‑headedness, especially on standing.
• Fatigue: general tiredness or reduced energy.
• Nasal congestion: feeling of a blocked nose.
• Peripheral edema: swelling of lower limbs.
• Nausea: mild stomach upset.

Serious or Rare Side Effects

• Bradycardia: abnormally slow heart rate that may require medical attention.
• Severe hypotension: marked drop in blood pressure leading to fainting.
• Bronchospasm: narrowing of airways, particularly in patients with asthma or COPD.
• Allergic reaction: rash, itching, or swelling.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for potential complications.

• Monitor blood pressure: regularly check to ensure therapeutic levels.
• Assess heart rate: watch for bradycardia, especially in patients with conduction disorders.
• Caution in hepatic impairment: dose adjustment may be needed in liver disease.
• Avoid abrupt discontinuation: taper under medical supervision to prevent rebound hypertension.
• Use with caution in asthma: β‑blockade may exacerbate bronchospasm.
• Store at room temperature: keep below 25°C, retain original packaging, protect from moisture.

Nebivolol can interact with several drug classes; careful review of a patient’s medication list is essential.

Major Interactions (Avoid)

• Combined use with other β‑blockers: may cause excessive bradycardia and hypotension.
• Concomitant calcium channel blockers (e.g., verapamil, diltiazem): increase nebivolol plasma levels.
• Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): can raise drug concentration leading to toxicity.

Moderate Interactions (Monitor Closely)

• Diuretics: may potentiate antihypertensive effect, requiring blood pressure monitoring.
• Antihyperglycemic agents: nebivolol may mask hypoglycemia symptoms.
• NSAIDs: can reduce antihypertensive efficacy of nebivolol.